Resistance to Cholesterol Gallstone Disease: Hepatic Cholesterol Metabolism
The Journal of Clinical Endocrinology & Metabolism · 15.03.2024 · 109 (4) · 912-923
DOI: 10.1210/clinem/dgad528 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 05.09.2023. Verfasst von Chenghao Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Biliary Surgery (2nd General) Unit, Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. Ch…. Hauptthemen laut MEDLINE: Gallstones, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 106 Literaturangaben. Gefördert von: Liaoning Science and Technology Plan Project, The 345 Talent Project Program of China Medical University Shengjing Hospital.
Abstract (Originalsprache)
Cholesterol gallstone disease (CGD) is one of the most common digestive diseases, and it is closely associated with hepatic cholesterol metabolism. Cholesterol gallstones may be caused by abnormal hepatic cholesterol metabolism, such as excessive cholesterol biosynthesis within the liver, interfering with the uptake or export of cholesterol in the liver, and abnormal hepatic cholesterol esterification. In this review, we begin with a brief overview of the clinical diagnosis and treatment of gallstone disease (GSD). Then, we briefly describe the major processes of hepatic cholesterol metabolism and summarize the key molecular expression changes of hepatic cholesterol metabolism in patients with gallstones. We review and analyze the recent advances in elucidating the relationships between these key molecules and CGD, and some targets significantly impacting on CGD via hepatic cholesterol metabolism are also listed. We also provide a significant discussion on the relationship between CGD and nonalcoholic fatty liver disease (NAFLD). Finally, the new discoveries of some therapeutic strategies associated with hepatic cholesterol metabolism to prevent and treat CGD are summarized.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biliary Surgery (2nd General) Unit, Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China.
- Innovation Institute of China Medical University, Shenyang 110122, P.R. China.
ORCID-Profile: Jing Kong
Förderung
- Liaoning Science and Technology Plan Project
- The 345 Talent Project Program of China Medical University Shengjing Hospital
Zitieren
APA
Zhang, C., Dai, W., Yang, S., Wu, S., & Kong, J. (2024). Resistance to Cholesterol Gallstone Disease: Hepatic Cholesterol Metabolism. The Journal of Clinical Endocrinology & Metabolism, 109(4), 912-923. https://doi.org/10.1210/clinem/dgad528
Vancouver
Zhang C, Dai W, Yang S, Wu S, Kong J. Resistance to Cholesterol Gallstone Disease: Hepatic Cholesterol Metabolism. The Journal of Clinical Endocrinology & Metabolism. 2024;109(4):912-923. doi:10.1210/clinem/dgad528
BibTeX
@article{Zhang2024,
author = {Zhang, Chenghao and Dai, Wanlin and Yang, Shaojie and Wu, Shuodong and Kong, Jing},
title = {Resistance to Cholesterol Gallstone Disease: Hepatic Cholesterol Metabolism},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2024},
volume = {109},
number = {4},
pages = {912--923},
doi = {10.1210/clinem/dgad528}
}
EUVIMED